TABLE 2.
Secondary endpoints: individual cancers.
| Treatment | Events/total | Control | Hazard ratio (95% CI) | |
|---|---|---|---|---|
| treatment | ||||
| Gastro-intestinal cancer a | Vitamin D | 11/1,076 | 11/1,081 | 1.00 (0.43–2.3) |
| Omega-3 | 8/1,073 | 14/1,084 | 0.59 (0.25–1.40) | |
| SHEP | 12/1,081 | 10/1,076 | 1.19 (0.51–2.7) | |
| Omega-3 + Vitamin D | 4/529 | 7/537 | 0.59 (0.18–1.98) | |
| Vitamin D + SHEP | 5/539 | 4/539 | 1.19 (0.37–3.8) | |
| Omega-3 + SHEP | 5/539 | 7/542 | 0.70 (0.21–2.3) | |
| All treatments | 1/264 | 4/270 | 0.70 (0.16–3.03) | |
| Breast cancer a | Vitamin D | 6/667 | 7/664 | 0.83 (0.28–2.48) |
| Omega-3 | 3/668 | 10/663 | 0.31 (0.08–1.12) | |
| SHEP | 6/665 | 7/666 | 0.87 (0.29–2.58) | |
| Omega-3 + Vitamin D | 1/330 | 5/326 | 0.26 (0.05–1.41) | |
| Vitamin D + SHEP | 2/332 | 3/331 | 0.72 (0.16–3.36) | |
| Omega-3 + SHEP | 1/337 | 5/335 | 0.27 (0.05–1.42) | |
| All treatments | 0/165 | 2/165 | 0.22 (0.03–1.66) | |
| Prostate cancer a | Vitamin D | 8/409 | 6/417 | 1.4 (0.48–4.05) |
| b Omega-3 | 2/405 | 12/421 | 0.17 (0.04–0.75) | |
| SHEP | 6/416 | 8/410 | 0.69 (0.24–1.99) | |
| Omega-3 + Vitamin D | 2/199 | 6/211 | 0.24 (0.04–1.46) | |
| Vitamin D + SHEP | 2/207 | 2/208 | 0.96 (0.22–4.16) | |
| b Omega-3 + SHEP | 0/202 | 6/207 | 0.12 (0.02–0.74) | |
| All treatments | 0/99 | 2/105 | 0.16 (0.02–1.33) |
a
Unadjusted.
b
Significant at 5% levels.
Cox-proportional hazard models are unadjusted due to the small numbers of cancer cases for the site-specific cancers.